Immune Checkpoint Inhibitors for Metastatic Colorectal Cancer: A Systematic Review

A. S. Gilson, Vincent Y. F. Tan, Thibaud Koessler, Jérémy Meyer, G. Meurette, Émilie Liot, Frédéric Ris, Vaihere DelauneCancers 2025 · DOI

TL;DR

This systematic review synthesizes current evidence on immune checkpoint inhibitors (ICIs) for metastatic colorectal cancer (mCRC). While ICIs have revolutionized treatment for microsatellite instability-high (MSI-H) mCRC, their efficacy in microsatellite stability (MSS) mCRC remains limited, highlighting the need for novel strategies and combination therapies.

What Problem Does This Paper Address?

Colorectal cancer (CRC) is a major global health concern, with metastatic disease (mCRC) carrying a poor prognosis. Immunotherapy, specifically immune checkpoint inhibitors (ICIs), has emerged as a promising treatment modality across various cancers. However, the effectiveness of ICIs in mCRC is not uniform, with a significant disparity observed between tumors with high microsatellite instability (MSI-H) and those with microsatellite stability (MSS). This review aims to consolidate the existing research on ICI efficacy and toxicity in mCRC, particularly focusing on how recent findings might influence current treatment guidelines. The challenge lies in understanding which mCRC subtypes benefit most from ICIs and how to overcome resistance in MSS tumors.

Methods

This study employed a systematic review methodology, adhering to the PRISMA 2020 guidelines. The researchers conducted an independent literature search across three major databases: MEDLINE, Web of Science, and Cochrane. The search focused on clinical trials and randomized controlled trials (RCTs) published between January 2019 and January 2025, using keywords related to "colorectal cancer," "immunotherapy," and "checkpoint inhibitor." The primary outcomes assessed were progression-free survival (PFS), overall survival (OS), and objective response rate (ORR). Studies involving other immunotherapy types, non-clinical trials, pre-clinical trials, and study protocols were excluded. Due to significant heterogeneity in intervention types, treatment regimens, patient populations, and outcome reporting, a meta-analysis was not conducted; instead, a qualitative synthesis of the findings was performed.

Datasets

Not discussed in the paper. This is a systematic review of published clinical trials, not a study that generated new datasets.

Key Insights and Ideas

  • MSI-H vs. MSS Divide: The most striking insight is the stark dichotomy in ICI response based on microsatellite status. MSI-H tumors, characterized by a high mutational burden, are highly responsive to ICIs, while MSS tumors remain largely resistant. This highlights the critical role of tumor mutational burden in predicting ICI efficacy.
  • Combination is Key for MSS: For MSS mCRC, monotherapy with ICIs shows minimal benefit. The focus is shifting towards combination strategies, exploring synergistic effects with chemotherapy, small molecule inhibitors, or other immunotherapies.
  • Toxicity Management is Crucial: While ICIs can be effective, combination regimens, especially those involving anti-CTLA-4 agents or multiple drugs, are associated with increased toxicity. Identifying predictive markers for both response and toxicity is paramount for optimizing patient selection and treatment.
  • Novel Agents and Strategies: The field is actively exploring novel approaches, including dual-target ICIs, bispecific antibodies, and strategies to modify the tumor microenvironment (e.g., anti-TGF-β, anti-CD73) to overcome resistance in MSS mCRC.

Key Results

The review identified 48 studies.

  • MSI-H mCRC: Checkpoint inhibitors demonstrated significant efficacy in MSI-H metastatic colorectal cancer. Pembrolizumab, in particular, showed a clear advantage as a first-line treatment in the KEYNOTE-177 trial, improving PFS and ORR. Nivolumab combined with ipilimumab also showed robust clinical benefits in MSI-H mCRC.
  • MSS mCRC: Immunotherapy was generally less effective in MSS mCRC. Combination strategies with chemotherapy or targeted therapies yielded mixed results, and often increased toxicity. For example, the IMblaze370 trial showed poor outcomes for atezolizumab in MSS mCRC.
  • Combination Regimens:
    • Anti-PD-1 + Anti-CTLA-4: Combinations like nivolumab + ipilimumab showed promise in MSI-H mCRC.
  • Anti-PD-L1 + Anti-CTLA-4: Tremelimumab + durvalumab showed limited differences compared to supportive care in MSS CRC with liver metastases, with higher rates of grade > 3 TRAEs.
  • ICI + Chemotherapy: Combinations showed potential for improving PFS and ORR in MSS mCRC, but often with increased toxicity.
  • ICI + Small Molecule Inhibitors: These combinations showed mixed results, with some demonstrating encouraging activity and others limited efficacy.
  • Toxicity: Grade > 3 treatment-related adverse events (TRAEs) were common, particularly in combination regimens. Diarrhea, fatigue, rash, and immune-related events were frequently reported.

Limitations and Future Work

The authors acknowledge several limitations:

  • Heterogeneity: The available evidence is heterogeneous in terms of tumor profiles (MSS vs. MSI), reporting of these profiles, and the combinations studied.
  • Small Sample Sizes: Many studies included have small sample sizes and diverse patient populations, limiting the generalizability of findings.
  • Lack of Comparative Control Groups: Some studies lack comparative control groups, making it difficult to definitively assess the benefit of novel combinations.
  • Distinction Between Colon and Rectal Cancer: The review did not distinguish between colon and rectal cancers, as most studies do not differentiate, despite their biological differences.
  • Prior Chemotherapy Information: Detailed information about prior chemotherapy received by patients was often not provided, which could impact efficacy interpretation.

Future work should focus on:

  • Deeper Exploration of Mechanisms: Understanding the underlying mechanisms of ICI resistance in MSS mCRC.
  • Better Patient Stratification: Developing more precise methods to stratify patients for optimal treatment selection.
  • Rigorous Clinical Trials: Conducting well-designed clinical trials to expand access and maximize benefits across all CRC subtypes.
  • Novel Strategies: Investigating approaches like converting MSS tumors to MSI, modifying the tumor microenvironment, and developing "anti-cancer" vaccines.
  • Predictive Tools: Developing robust predictive tools for both response and toxicity to optimize patient selection and treatment.

Summary updated

Abstract

Immunotherapy has revolutionized MSI mCRC treatment while treating MSS CRC with these molecules remains unconvincing. Combination strategies and novel agents may offer potential but require further research to prove efficacy.
BibTeX
@inproceedings{gilson2025immune,
  author = {A. S. Gilson and Vincent Y. F. Tan and Thibaud Koessler and Jérémy Meyer and G. Meurette and Émilie Liot and Frédéric Ris and Vaihere Delaune},
  title = {{Immune Checkpoint Inhibitors for Metastatic Colorectal Cancer: A Systematic Review}},
  booktitle = {Cancers},
  year = {2025},
  doi = {10.3390/cancers17132125},
}
Figure